Fungal Bloodstream Co-infection by Trichosporon asahii in a COVID-19 Critical Patient: Case Report and Literature Review

Benelli, Jéssica Louise; Basso, Rossana Patrícia; Grafulha, Talita Werner; Poester, Vanice Rodrigues; Munhoz, Lívia Silveira; Martins, Katheryne Benine; Zogbi, Heruza Einsfeld; Groll, Andréa von; Severo, Cecília Bittencourt; Stevens, David A.; Xavier, Melissa Orzechowski

doi:10.1007/s11046-022-00637-6

Cited by 11 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients in this study received broad-spectrum antibiotic therapy and systemic corticosteroids, and 55.5% received antifungals previously. The mortality rate was 77.7% [90]. T. dohaense caused brain abscess associated with COVID-19, a rare infection not previously described, in the central nervous system of a diabetic patient aged 55 years [93].…”

Section: Trichosporon Sppmentioning

confidence: 82%

“…During the SARS-CoV-2 pandemic, there were co-infections with Trichosporon asahii in North America [88], South America [89,90], Europe [91], and the Middle East [92], presenting as nosocomial pneumonia [91], fungemia [89,92], or urinary tract infection [88]. All patients in this study received broad-spectrum antibiotic therapy and systemic corticosteroids, and 55.5% received antifungals previously.…”

Section: Trichosporon Sppmentioning

confidence: 96%

See 1 more Smart Citation

Clinical Challenges of Emerging and Re-Emerging Yeast Infections in the Context of the COVID-19 Pandemic

et al. 2022

View full text Add to dashboard Cite

During the geological eras, some fungi, through adaptation and/or environmental/ecological pressure, interacted directly and indirectly with humans, through occasionally harmful interaction interdependent on the individual’s immunological condition. Infections caused by yeasts are underreported, subjugated, and underdiagnosed, and treatment is restricted to a few drugs, even after the significant progress of medicine and pharmacology. In the last centuries, antagonistically, there has been an exponential increase of immunocompromised individuals due to the use of immunosuppressive drugs such as corticosteroids, increased cases of transplants, chemotherapeutics, autoimmune diseases, neoplasms, and, more recently, coronavirus disease 2019 (COVID-19). This review aims to survey emerging and re-emerging yeast infections in the current clinical context. Currently, there is an immense clinical challenge for the rapid and correct diagnosis and treatment of systemic mycoses caused by yeasts due to the terrible increase in cases in the current context of COVID-19.

show abstract

Section: Trichosporon Sppmentioning

confidence: 82%

Section: Trichosporon Sppmentioning

confidence: 96%

Clinical Challenges of Emerging and Re-Emerging Yeast Infections in the Context of the COVID-19 Pandemic

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Since the lung is the main affected organ in COVID-19 patients, Candida colonization following immunosuppressive treatments and antibacterial medications can lead to overgrowth and morphogenesis of Candida spp. due to induced defects in cell-mediated immunity of the respiratory epithelium [ 36 – 39 ].…”

Section: Discussionmentioning

confidence: 99%

Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates

et al. 2022

View full text Add to dashboard Cite

Introduction Fungal co-infections are considered an important complication in hospitalized patients with SARS-CoV-2 that can be attributed to disease aggravation, increased mortality, and poor outcomes. This study was conducted to determine the species distribution and antifungal susceptibility patterns of Candida isolates from hospitalized COVID-19 patients in Shiraz, Iran, in addition to associated risk factors and outcomes of co-infections with Candida species. Materials and Methods In this single-center study, a total of 106 hospitalized COVID-19 patients were evaluated for clinical characteristics and outcomes. Species identification was performed by ITS1-5.8S-ITS2 gene sequencing. Antifungal susceptibility testing to fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, amphotericin B, and nystatin was determined according to the M27-A3/S4 CLSI protocol. Results Candida species were recovered from 48% (51/106) of hospitalized COVID-19 patients. Statistical analysis showed that patients who had heart failure, bacterial co-infection, and were receiving empirical antifungal therapy had a higher risk of developing Candida co-infection. In total, 71 Candida isolates were recovered, of which C. albicans (69%) was the most prevalent isolate. The majority of the Candida isolates were susceptible to all classes of tested antifungal drugs. Discussion Our results elucidate a high rate of Candida co-infections among hospitalized COVID-19 patients. Comorbidities such as heart failure, HTN, COPD, bacterial infections as well as therapeutic interventions including catheterization, mechanical ventilation, and ICU admission increased the risk of Candida spp. isolation from the bloodstream, respiratory tract and urine samples, which led to a higher in-hospital mortality rate. Additionally, obtained data clarified that empirical antifungal therapy was not as successful as anticipated.

show abstract

“…Benelli and researchers [50] reported a case of a patient with bloodstream infection by T. asahii in a critically ill patient with COVID-19 associated with Acinetobacter baumanii. Almeida-Jr. [51], described 5 critical patients with COVID-19 who developed fungemia by T. asahii, who presented risk conditions: central venous catheter, previous exposure to broad-spectrum antibiotics, previous therapy with echinocandin and previous prolonged corticosteroid therapy.…”

Section: Reports Of Immunosuppression In Cases Of Sars-covmentioning

confidence: 99%

Challenges of the Global COVID-19 Pandemic and Invasive Fungal Pathogens in SARS-COV-2 Associations: A Dangerous Relationship

Mariscal¹,

Matias²,

Almeida³

et al. 2023

AiM

View full text Add to dashboard Cite

Background: COVID-19 is a rapidly transmissible pneumonia-like illness caused by SARS-CoV-2 that out broke in China in 2019 and is currently circulating worldwide. In the current context of the SARS-CoV-2 pandemic, complications are observed in clinical settings for the treatment of severe COVID-19 disease in nosocomial settings, due to cases of fungal co-infections. Objective: To carry out a review on fungal infections associated with respiratory infections caused by COVID-19 (Sars-Cov-2) and their aggravation. Methodology: The purpose of this study is to inform the reader about the characteristics of SARS-CoV-2 and the main fungal species that are affecting patients undergoing treatment for severe COVID-19, provoking discussion of the importance of the proposed topic, in relation to co-infections by different fungal microorganisms. Result: 80 scientific studies were selected, resulting from patients with COVID-19 and most commonly observed in patients with a history of comorbidities such as diabetes mellitus, hypertension, kidney disease, severe liver disease, oncological diseases, obesity and with severe COVID-19. These data do not represent the total number of records of the disease in the world, but cases reported by researchers in their series, showing the overlapping of fungal co-infection through the compromised immune status due to the use of therapeutic drugs, dysregulation of the microbiota, How to cite this paper: Mariscal, A.

show abstract

Fungal Bloodstream Co-infection by Trichosporon asahii in a COVID-19 Critical Patient: Case Report and Literature Review

Cited by 11 publications

References 19 publications

Clinical Challenges of Emerging and Re-Emerging Yeast Infections in the Context of the COVID-19 Pandemic

Clinical Challenges of Emerging and Re-Emerging Yeast Infections in the Context of the COVID-19 Pandemic

Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates

Challenges of the Global COVID-19 Pandemic and Invasive Fungal Pathogens in SARS-COV-2 Associations: A Dangerous Relationship

Contact Info

Product

Resources

About